Vaxart Inc (VXRT) - News Archive

Promising Developments Despite Financial Hurdles: Vaxart’s Advancements in Norovirus Vaccine ResearchIn the complex landscape of pharmaceuticals and vaccine development, financial metrics often cast a long shadow over t...

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): A Strategic Move to Attract Talent Amid Market ChallengesSOUTH SAN FRANCISCO, Calif. March 27, 2025 Vaxart, Inc. (Nasdaq: VXRT) announced on M...

Vaxart Inc. has recently announced the publication of an important study showcasing the immunogenicity and safety of its first-generation oral pill Norovirus vaccine candidate, particularly focusing on elderly adults. T...

: This article presents an overview of recent developments in Vaxart s COVID-19 vaccine research, following the favorable review from an Independent Data Safety Monitoring Board (DSMB) regarding the initial safety asses...

In a strategic move to attract top talent, Vaxart, Inc. (Nasdaq: VXRT) announced on November 19, 2024, that its Compensation Committee has granted inducement equity awards, totaling 91,500 shares of common stock. These...

Evaluation of Vaxart s Next-Generation Oral COVID-19 Vaccine: Initiation of Phase 2b Sentinel CohortVaxart Inc. has recently announced the commencement of the 400-subject sentinel cohort for its Phase 2b study, designed...

Promoting Talent Acquisition:The Compensation Committee of Vaxart s Board of Directors, responsible for overseeing compensation and benefits, believes that attracting and retaining exceptional employees is vital to the...

In a recent announcement, Vaxart, Inc. unveiled plans for an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share. The gross proceeds from this offering are expected to...

Vaxart Awarded Up to $453 Million by BARDA for Groundbreaking Phase 2b Study on COVID-19 Oral Pill Vaccine Vaxart, a dynamic player in the innovative field of vaccine development, has recently announced a significant mi...

Vaxart, Inc. Grants Inducement Equity Awards to New Employee: Impact on Share PriceThe recent press release from Vaxart, Inc. revealed that the company granted 22,500 shares of its common stock to a new non-executive em...

for CSIMarket.com :In recent developments in vaccine research, Vaxart has announced positive results for its bivalent norovirus vaccine candidate in lactating mothers. This breakthrough suggests a potential pathway to p...

Vaxart, a California-based biotechnology company, has recently announced a major capital injection of $9.27 million courtesy of the Biomedical Advanced Research and Development Authority (BARDA). This substantial commit...

In a bold move to secure its financial future and accelerate growth, Vaxart, Inc. (Nasdaq: VXRT) announced a significant registered direct offering with RA Capital Management. The company aims to raise $10.0 million by...